loader
Please Wait
Applying Filters...

Annual Sales of Lisdexamfetamine reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Menu
$ API Ref.Price (USD/KG) : 3,811Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1Vyvanse/Elvanse

PharmaCompass

01

Brand Name : Vyvanse

Lisdexamfetamine

arrow
Pharmaconex 2024
Not Confirmed

02

Brand Name : Vyvanse

Lisdexamfetamine Dimesylate

arrow
Pharmaconex 2024
Not Confirmed

Brand Name : Vyvanse

arrow
Pharmaconex 2024
Not Confirmed

Lisdexamfetamine Dimesylate

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2020 Revenue in Millions : 2

2019 Revenue in Millions : 0

Growth (%) : New Launch in Japan

blank

03

Brand Name : Vyvanse

Lisdexamfetamine

arrow
Pharmaconex 2024
Not Confirmed

04

Brand Name : Vyvanse/Elvanse

Lisdexamfetamine

arrow
Pharmaconex 2024
Not Confirmed

05

Brand Name : Vyvanse

Lisdexamfetamine Dimesylate

arrow
Pharmaconex 2024
Not Confirmed

06

Brand Name : Vyvanse/Elvanse

Lisdexamfetamine

arrow
Pharmaconex 2024
Not Confirmed

07

Brand Name : Vyvanse

Lisdexamfetamine Dimesylate

arrow
Pharmaconex 2024
Not Confirmed

08

Brand Name : Vyvanse/Elvanse

Lisdexamfetamine Dimesylate

arrow
Pharmaconex 2024
Not Confirmed

09

Brand Name : Vyvanse

Lisdexamfetamine Dimesylate

arrow
Pharmaconex 2024
Not Confirmed

Brand Name : Vyvanse

arrow
Pharmaconex 2024
Not Confirmed

Lisdexamfetamine Dimesylate

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2016 Revenue in Millions : 2,014

2015 Revenue in Millions : 1,722

Growth (%) : 17

blank

10

Brand Name : Vyvanse

Lisdexamfetamine Dimesylate

arrow
Pharmaconex 2024
Not Confirmed

Brand Name : Vyvanse

arrow
Pharmaconex 2024
Not Confirmed

Lisdexamfetamine Dimesylate

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2017 Revenue in Millions : 2,161

2016 Revenue in Millions : 2,014

Growth (%) : 7

blank